Pathways to tamoxifen resistance

被引：218

作者：

Riggins, Rebecca B.

Schrecengost, Randy S.

Guerrero, Michael S.

Bouton, Amy H.

机构：

[1] Univ Virginia, Hlth System, Dept Microbiol, Charlottesville, VA 22908 USA

[2] Univ Virginia, Hlth System, Ctr Canc, Charlottesville, VA 22908 USA

[3] Georgetown Univ, Lombardi Comprehens Canc Ctr, Dept Oncol, Washington, DC 20057 USA

来源：

CANCER LETTERS | 2007年 / 256卷 / 01期

关键词：

tamoxifen; antiestrogen; aromatase inhibitor; fulvestrant; estrogen receptor;

D O I：

10.1016/j.canlet.2007.03.016

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Therapies that target the synthesis of estrogen or the function of estrogen receptor(s) have been developed to treat breast cancer. While these approaches have proven to be beneficial to a large number of patients, both de novo and acquired resistance to these drugs is a significant problem. Recent advances in our understanding of the molecular mechanisms that contribute to resistance have provided a means to begin to predict patient responses to these drugs and develop rational approaches for combining therapeutic agents to circumvent or desensitize the resistant phenotype. Here, we review common mechanisms of antiestrogen resistance and discuss the implications for prediction of response and design of effective combinatorial treatments. (C) 2007 Elsevier Ireland Ltd. All rights reserved.

引用

页码：1 / 24

页数：24

共 221 条

[1] Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p2l, p27, and antiestrogens in breast cancer [J].